Pharma BD Deal Intelligence
A win for AI-sourced dealmaking: Pathos's Foundry platform flagged DO-2, which showed 100% tumor shrinkage in evaluable MET exon 14 NSCLC patients with just a 5% peripheral edema rate versus 62-82% for competitors, though financial terms stayed undisclosed.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI. The financing positions Pathos to execute its Foundry…
Pathos AI announced the acquisition of a majority stake in DeuterOncology, a Belgium-based company developing DO-2, a third-generation MET kinase inhibitor for…
DO-2 is a third-generation MET kinase inhibitor that demonstrated 100% tumor shrinkage in all evaluable MET exon 14 skipping NSCLC patients with only…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Pathos AI acquired a majority stake in Belgium-based DeuterOncology to advance DO-2, a deuterated third-generation MET kinase inhibitor identified through Pathos's Foundry AI platform. DO-2 targets MET-altered NSCLC and other solid tumors with a profile designed to reduce the peripheral edema seen in current MET inhibitors. Financial terms were not disclosed.
7K US cases/yr · $350M Estimated 2024 US MET-altered NSCLC TKI market (Tabrecta + Tepmetko proxy)
MET exon 14 skipping mutations occur in approximately 3% of all NSCLC cases and define a distinct oncogene-driven subset. Current MET TKIs (capmatinib/Tabrecta, tepotinib/Tepmetko, savolitinib/Orpathys) deliver meaningful response rates but are limited by peripheral edema affecting 62-82% of patients — often requiring dose reductions or discontinuation — and by acquired resistance in roughly one-third of patients. Next-generation MET inhibitors with improved tolerability and resistance coverage represent a clear unmet need.
MET-altered NSCLC is led by Novartis (Tabrecta/capmatinib) and Merck KGaA (Tepmetko/tepotinib) with AstraZeneca's Orpathys (savolitinib) in select markets. Both incumbents suffer from class-wide peripheral edema. Next-gen entrants include AbbVie (telisotuzumab vedotin, ADC), Janssen (amivantamab in EGFR-MET), and select Chinese MET inhibitors. DO-2's deuterated chemistry and fast on/off kinetics target the tolerability gap. Patent protection through December 2040 provides extended runway.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pathos AI, Inc. / DeuterOncology N.V. (this deal) | 2026 | — | — |
| Pathos AI, Inc. / Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | 2026 | $2.2B | — |
| Pathos AI, Inc. / AstraZeneca PLC | 2026 | — | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
← Browse all deals · How we score deals
More: 2026 deals · Pathos AI, Inc. deals · Oncology deals